|
GB201001203D0
|
|
Use of pharmaceutically active compounds
|
|
GB0913427D0
|
|
Compounds for treatment of imflammation
|
|
GB0905098D0
|
|
Use of biomarkers
|
|
WO2008118087A1
|
|
Peptide for differentiating osteoarthritis from rheumatoid arthritis and non-disease conditions
|
|
US2008220459A1
|
|
Diagnosis of collagen IX destruction
|
|
US2008241851A1
|
|
Cartilage intermediate layer protein 2 C1 and its use to differentiate osteoarthritis from rheumatoid arthritis and non-disease conditions
|
|
ZA200609223B
|
|
Modulation of cartilage homeostasis
|
|
NZ550893A
|
|
Use of chondroitin sulphate E (CS-E) for the treatment of diseases or conditions related to collagen fibril formation
|
|
GB0505641D0
|
|
Treatment of autoimmune and inflamatory diseases
|
|
WO2004099784A2
|
|
Method for determining a tissue degradation process by detection of fibromodulin neoepitopes
|
|
US7211649B1
|
|
Cartilage intermediate layer protein
|
|
CA2392175A1
|
|
A conjugate of a collagen ii-binding fragment and an arthritis-affecting pharmaceutical substance
|
|
EP1232394A1
|
|
Sandwich immunoassay and monoclonal antibodies for comp, cartillage oligomeric matrix protein
|
